Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-08-05

Clinical Trial Update: Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating inhaled interferon α2b for treating COVID-19 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Interferon alfa-2b (interferon alfa-2b)

Snippet

Sponsor: Pontificia Universidad Catolica de Chile | Conditions: Coronavirus Disease 2019 | Phase 1, Phase 2 | Status: COMPLETED